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In an attempt to establish the protection afforded by regular salmeterol use against induced bronchoconstriction in 
asthmatic patients, a meta-analysis was conducted on nine double-blind clinical trials that fulfilled the inclusion 
criteria. 
In each trial, subjects were randomly assigned to receive either salmeterol 50 ug twice daily or a comparator 
(placebo or salbutamol). Two hundred and twenty-five asthmatic subjects had at least one PC,, or PD,, (histamine 
or methacholine concentration or dose producing 20% fall in forced expiratory volume in 1 s) measurement recorded 
within 1 h to 16 weeks after the first dose, and up to 31 days after the last dose, of medication. 
One hour after the first dose of salmeterol, there was a 3.5-fold increase in doubling dose compared to baseline. 
Within 12 h of the first dose, the level of protection was 1.5 doubling doses, and protection was maintained at 0.5-1.5 
doubling doses over 16 weeks’ treatment. This level of protection was maintained for up to 60 h after the last dose. 
At no time during the washout period did the level of protection fall below zero. Salmeterol afforded significantly 
greater protection at all time points during the treatment period than comparator agents, but there was no significant 
difference during the washout period. 
In conclusion, salmeterol affords protection against bronchoconstrictor stimuli, and any reduction in this 
bronchoprotective effect occurred during the first few days of treatment. During long-term salmeterol treatment, 
there was maintained significant protection that showed no evidence of attenuation after 16 weeks’ treatment. 
Furthermore, there was no evidence of rebound deterioration in bronchial responsiveness after cessation of 
salmeterol treatment. 
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Introduction 
Asthma is a chronic disease that manifests itself as episodic 
dyspnoea, wheezing and cough. Pathophysiologically, 
asthma is characterized by variable airway obstruction that 
is associated with an exaggerated response to various bron- 
choconstrictor stimuli (1). This airway hyper-responsiveness 
takes the form of increases in both the sensitivity and the 
maximal response of the airways to stimuli such as inhaled 
histamine or methacholine (2). Irrespective of the stimulant 
triggering bronchoconstriction, in most situations the 
pathophysiological end response is an increase in airway cell 
inflammatory burden. As a result, current therapeutic 
guidelines for the management of asthma are directed 
against the inflammatory process by using inhaled 
corticosteroids. For symptom relief, intermittent use of 
short-acting &agonists is recommended (3). 
Recently, two long-acting &agonists, salmeterol and 
formoterol, have become available. Salmeterol has been 
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shown to increase morning and evening peak how, reduce 
diurnal variations in peak flow, alleviate the symptoms of 
asthma and reduce the requirement for additional bron- 
chodilator therapy (4,5). The bronchodilator activity of 
salmeterol lasts for up to 12 h, whereas conventional 
/3,-agonists are effective for only 4-5 h (6,7). Thus, sal- 
meterol, administered at a dose of 50 ,ug twice daily from a 
metered-dose inhaler or in powder form, has been shown to 
be an effective long-acting bronchodilator for the manage- 
ment of asthma symptoms. A similar long duration of 
action has been shown for its protective effects against 
bronchoconstrictor stimuli such as inhaled histamine (8), 
methacholine (9), allergen (lo), hyperventilation with dry 
cold air (11) and exercise (12). In addition, salmeterol has 
been shown to decrease the activity of eosinophils in 
bronchoalveolar lavage fluid (13), and in vitro salmeterol 
has been reported to inhibit inflammatory mediator release 
from sensitized human lung tissue and from stimulated 
alveolar macrophages (14,15). These results indicate that 
long-term treatment with salmeterol could have. beneficial 
effects on airway hyper-responsiveness in asthma. 
A variety of studies have examined the protection 
afforded by the long-term use of salmeterol against 
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subjects Trial design Comparator 
Treatment 
duration Reference 
1 Adults 24 Parallel Placebo 8 weeks 19 
2 Adults 19 Parallel Placebo 8 weeks 17 
3 Adults 12 Crossover Placebo 4 weeks 13 
4 Adults 19 Parallel Salbutamol 6 weeks 16 
5 Children 30 Parallel Salbutamol 16 weeks 23 
6 Adults 22 Parallel Placebo 6 weeks 22 
7 Adults 34 Parallel Placebo 8 weeks 18 
8 Children 40 Parallel Placebo 16 weeks 21 
9 Children 25 Parallel Salbutamol 6 weeks 20 
histamine- or methacholine-induced bronchoconstriction, 
and whether tolerance develops to this effect. The aim of 
this meta-analysis was to use nine of these studies (13,16- 
23) which met pre-defined inclusion criteria, to establish 
the level of maintained protection afforded by long-term 
regular use of salmeterol against histamine- or 
methacholine-induced bronchoconstriction, and to assess 
bronchial reactivity following withdrawal of long-term 
salmeterol therapy. 
Methods 
Nine double-blind clinical trials performed before 
December 1994 by Glaxo Research and Development, in 
which a total of 225 asthmatic patients (adults and children) 
were randomly assigned to receive either salmeterol 50,ug 
twice daily or a comparator, were combined in a meta- 
analysis to establish the protection afforded by regular 
salmeterol use against histamine- or methacholine-induced 
bronchoconstriction. Inclusion criteria were: double-blind, 
randomized trial of either parallel or crossover design, of 
at least 4 weeks duration; patients receiving long-term 
salmeterol 50,~g twice daily in one of the treatment arms; 
and at least one assessment of bronchial reactivity to 
histamine or methacholine challenge during the trial. Table 
1 summarizes the nine trials according to the trial design, 
patient, sample size, age group, duration of treatment and 
comparator drug. 
In eight of the trials, subjects entered a double-blind 
parallel treatment period and were randomly allocated, 
in equal numbers, to either salmeterol 50,ug twice daily 
or a comparator treatment (either placebo or salbutamol). 
Trial 3 was of a double-blind crossover design, with sub- 
jects randomly assigned to either salmeterol or placebo 
for a 4-week period, before receiving the alternative 
treatment for a further 4 weeks. Only data for the first 
period of the trial was used in the meta-analysis. Trial 9 
consisted of two phases, the first of which adopted a 
crossover design in which patients were randomly allocated 
to salmeterol 25 or 5Opg, or placebo, to compare the 
duration of action of salmeterol and to examine the 
safety of inhaled salmeterol when used prophylactically 
before physical activity in children with exercise-induced 
asthma. In the second phase, subjects were randomly 
allocated to either salmeterol 50,~g twice daily, or salbuta- 
mol 200,~g twice daily, in a B-week parallel trial. Only 
data from this latter phase of the trial were used in the 
meta-analysis. 
Analysis 
To combine the nine trials for the meta-analysis, the 
effect of treatment on each patients was measured by the 
doubling dose change, which was defined for each visit 
(DDvisit), as: 
DD,iSit=log,,(PC,, or PD,, at visit) - log,,(PC,, or PD,, 
at baseline)/log,,2 
where PC,, was defined as the concentration of histamine 
or methacholine that produced a 20% fall in forced expira- 
tory volume in 1 s (FEV,), and PD,, was defined as the 
dose of histamine or methacholine that produced a 20% fall 
in FEV,. In each study, either the PC,, or the PD,, values 
were recorded for the duration of the trial. 
Measurements of PC,, and PD,, were recorded within 
1 h to 16 weeks after the first dose of medication, and up to 
31 days after the last dose of medication. However, the 
number and scheduling of patient visits was not consistent 
over the nine trials. In trial 4, a study designed to evaluate 
the short-term rebound deterioration in airway responsive- 
ness following cessation of treatment, PD,, values were 
recorded three times during the washout period (24 h, 72 h 
and 2 weeks after the last dose of medication) but never 
during treatment. In contrast, subjects in trials 3 and 7 had 
at least one PC,, or PD,, value recorded during the 
treatment period but not during the washout period. In all 
other studies, PC,, or PD,, values were recorded at least 
once during both the treatment and washout periods. In 
trial 8, the PC,, value was measured at 4 pm and 4 am at 
baseline and after 16 weeks’ treatment, and the PC,, value 
at 4 pm was measured after 8 h, 1 week and 8 weeks. 
Measurements were also recorded at 8 am and 4 pm within 
24 h of completion of treatment, and against at 4 pm 1 week 
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FIG. 1. Mean change in doubling dose during treatment and washout periods for salmeterol (a) and comparator (0) 
drug. Numbers indicates trial number (see Table 1). 
later. Only the measurements taken at 4 pm were used in 
the meta-analysis. 
The meta-analysis examined the difference between the 
treatment groups over five time intervals: up to 1 h after the 
first administered dose; between 1 and 12 h after the first 
dose; during treatment; up to 60 h after the last adminis- 
tered dose (early washout); and more than 60 h after the 
last administered dose (late washout). Measurement during 
the ‘on treatment’ interval consisted of those recorded at, or 
before, 8 weeks of trial treatment but at least 12 h after 
commencing treatment; the latest measurement available in 
this time interval was considered for the analysis. No 
measurements taken later than 8 weeks after commencing 
treatment were used for this grouping. Similarly, the latest 
measurement available up to 14 days, but not before 60 h, 
of ceasing treatment was taken for the ‘more than 60 h after 
last dose’ group. 
Information for each of time interval was pooled from 
the individual trials using the equations: 
z=cw,q 
Var(r) = Cwi2 cr’ 
where ri represents the difference in the mean doubling dose 
between salmeterol and comparator agent for trial i, z is the 
overall weighted mean effect size, ~2 is the variance of the 
estimated mean difference and wi is the weight used for trial 
i subject to the condition that Cw,=l. The 100(1-a)% 
confidence interval (C) for the overall weighted mean effect 
in each time interval is then given by: 
where C,, is the two-tailed critical value of the standard 
normal distribution. 
This method of pooling assumes that each of the treat- 
ment estimates may be regarded as being normally distrib- 
uted with known variance, Var(r). In this analysis, equal 
weighting per trial is used, i.e. w= l/n, where n is the number 
of trials at the relevant timepoint. 
Results 
The mean changes in doubling dose (from baseline) during 
the various treatment and washout periods for each trial are 
shown in Fig. 1. The combined mean doubling dose values 
at each timepoint for salmeterol and comparator drug 
during the treatment and the washout periods are shown in 
Fig. 2. Salmeterol had a protective effect on airway reac- 
tivity to bronchoconstrictor stimuli, as indicated by a 
positive doubling dose value (i.e. an increase in PC,, or 
PD,, value on treatment compared to baseline). One hour 
after the first dose, the protective effect of salmeterol was 
approximately 35 doubling doses. Within 12 h of the first 
dose, the level of protection was 1.5 doubling doses, with a 
maintained level of protection between 0.5 and 1.5 doubling 
doses that persisted for 16 weeks of treatment. Further- 
more, salmeterol had a protective effect for up to 60 h after 
the last dose. At no time during the washout period did the 
level of protection fall below zero, thus showing no 
evidence of a rebound effect on cessation of treatment. 
Comparisons of the treatment differences between salm- 
eterol and comparator agent indicated that salmeterol 
afforded significantly greater protection at all timepoints 
during treatment, but there was no significant difference 
during the washout period. 
Two of the nine trials measured PC,, or PD,, 1 h after 
the first dose, three trials took these measurements between 
1 and 12 h after commencing treatment, and eight trials 
were included in the ‘on treatment’ phase. Four trials had 
measurements taken up to 60 h after administration of 
the last dose, and seven trials more than 60 h after the last 
dose of drug administration. The overall mean difference 
in doubling dose between salmeterol and comparator 
agent, together with 95% confidence limits, for each time 
interval in the meta-analysis are shown in Fig. 3. These 
confidence intervals indicate that salmeterol afforded 
significantly greater protection over the comparator 
agent at all time points during treatment, with the 
greatest difference in mean doubling dose being observed 
up to 1 h after the first administered dose. No significant 
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FIG. 2. Combined mean doubling dose values at each time point for salmeterol (0) and comparator (0) drug during treat- 
ment and washout periods. 
difference in mean doubling dose was observed after stop- 
ping trial treatment. 
Discussion 
The various clinical trials used in this meta-analysis have all 
reported that inhaled salmeterol 50 pug twice daily maintains 
its bronchodilator properties during long-term treatment in 
patients with asthma. However, with regard to its protective 
effects against bronchoconstrictor stimuli (either inhaled 
methacholine or histamine), tolerance to the effects of 
long-term salmeterol have been reported in some (19,23) 
but not all (17,24) studies. The results of this meta-analysis 
demonstrate that during long-term regular treatment 
with salmeterol 5Opg twice daily, there is significant, 
sustained (2 16 weeks) protection against histamine- or 
methacholine-induced bronchoconstriction. The protective 
effects of salmeterol against a bronchoconstriction were 
greatest for up to 1 h after the first dose, and any subse- 
quent reduction in this protective effect, which has been 
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FIG. 3. Mean difference and 95% confidence interval 
between mean doubling dose of salmeterol and compara- 
tor drug at each time interval. 
reported in several studies (see 19), was partial and occurred 
during the first few days of treatment. Overall, the protec- 
tive effects of salmeterol were maintained throughout treat- 
ment. This suggests that in addition to short-term 
bronchodilatation, salmeterol also affords protection 
against newly encountered stimuli that can induce 
bronchoconstriction. 
Cheung et al. (19) were the first to report the develop- 
ment of tolerance to the bronchoprotective effect of 
salmeterol against histamine challenge during treatment 
(5Opg twice daily for several weeks); however, the bron- 
codilator response of salmeterol was maintained. This study 
showed the bronchoprotective effect of salmeterol 
decreased from 3.3 doubling doses at 1 h post treatment to 
1.0 doubling dose after 4 and 8 weeks of continuous 
treatment. Other studies have also reported the develop- 
ment of tolerance to salmeterol (l&23-25). In addition, 
a study examining formoterol, another long-acting 
&agonist, has indicated that tolerance to the broncho- 
protective effect of this drug also occurs during the first few 
days of treatment (26). The available data suggest that 
tolerance to salmeterol develops within the first few days of 
treatment (24), with residual protection against metha- 
choline challenge (l-2 doubling doses) remaining for 
at least 4 months (23). Co-administration of inhaled 
corticosteroids does not prevent the development of 
tolerance (l&25). At present, the clinical relevance of this is 
not clear. 
Following cessation of salmeterol treatment, there was 
no sustained improvement in airway hyper-responsiveness, 
as has been observed with inhaled steroids (27-29). How- 
ever, it should be noted that within the first 60 h following 
cessation of treatment, there is a tendency towards a 
protective effect of salmeterol. There has been some con- 
cern that regular &-agonist monotherapy may result in 
reduced disease control, especially after stopping treatment 
(or changing to anon-j&-agonist) (30). However, the results 
of this study and other (16,19,22) indicate that there is no 
rebound deterioration in bronchial responsiveness after 
cessation of salmeterol therapy. 
In summary, this meta-analysis suggests that during 
long-term regular salmeterol treatment, there is 
significant, sustained bronchial protection over at least 4 
months. Any reduction in the protective effect afforded by 
salmeterol is partial and occurs during the first few days of 
treatment. In addition, there is no evidence of rebound 
deterioration in bronchial responsiveness after stopping 
salmeterol treatment. Thus, salmeterol is a safe and effec- 
tive treatment for asthma that, in addition to its proven 
bronchodilator activity, has protective effects against 
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